Earnings Preview: Diebold Nixdorf, Incorporated (DBD) Q2 Earnings Expected to Decline

Diebold Nixdorf, Incorporated (DBD) is expected to report a significant year-over-year decline in its Q2 2025 earnings and revenue, with consensus estimates at $0.61 EPS (-47.4% YoY) and $886.1 million revenue (-5.7% YoY). The August 6 earnings release will be critical for near-term stock performance, as actual results relative to these subdued expectations will drive price action. Given a 0% Earnings ESP and a Zacks Rank of #3, combined with a history of missing consensus EPS estimates in three of the last four quarters, DBD is not considered a compelling candidate for an earnings beat, suggesting potential downside risk if results align with or fall below current forecasts.

Analysis

Diebold Nixdorf, Incorporated (DBD) is positioned for a significantly weak financial report for the quarter ending June 2025, with consensus estimates forecasting a 47.4% year-over-year decline in earnings per share to $0.61 and a 5.7% decrease in revenue to $886.1 million. The outlook is further dampened by a lack of positive estimate revisions from covering analysts over the past 30 days, resulting in an Earnings ESP of 0%. This neutral signal, combined with a Zacks Rank of #3 (Hold), provides no statistical basis to expect an earnings beat. The company's historical performance reinforces this cautious view, as it has surpassed consensus EPS estimates only once in the last four quarters, including a notable -87.27% miss in the most recent period. Consequently, the combination of negative growth expectations, stagnant analyst sentiment, and a poor track record of execution suggests a heightened risk of disappointment in its upcoming August 6 earnings release.

Key Decisions for Investors

• Given the substantial expected declines in earnings and revenue and the company's poor history of meeting forecasts, investors should exercise caution and consider reducing exposure ahead of the earnings event on August 6.
• The primary focus for investors should be on management's forward-looking guidance and discussion of business conditions, as any sustained stock move will depend more on the future outlook than on the widely expected weak quarterly results.
• Since predictive models indicate DBD is not a compelling candidate for a positive earnings surprise, initiating or holding a long position solely in anticipation of a beat carries significant downside risk.